Jonathan L. Halperin, MD, FACC, FAHA, MSVM


Robert and Harriet Heilbrunn Professor of Medicine at Mount Sinai School of Medicine

Director of Clinical Cardiology Services in the Zena and Michael A. Wiener Cardiovascular Institute at The Mount Sinai Medical Center

Dr. Jonathan L. Halperin is the Robert and Harriet Heilbrunn Professor of Medicine at Mount Sinai School of Medicine at the Zena and Michael A. Wiener Cardiovascular Institute at The Mount Sinai Medical Center. He played a key role in the formation of Mount Sinai’s Cardiovascular Institute, a leading center for integrated cardiovascular research, education and patient care, and serves as Associate Director.

Dr. Halperin was the principal cardiologist responsible for the Stroke Prevention in Atrial Fibrillation (SPAF) clinical trials, was Co-Chairman of the Executive Steering Committee of the SPORTIF trials, which evaluated the first oral direct thrombin inhibitor for prevention of stroke in patients with AF and has been a member of Executive and Steering Committees of trials evaluating oral factor Xa inhibitors for this indication.

Past-President of the Society for Vascular Medicine and the New York City Affiliate of the American Heart Association, Dr. Halperin was the recipient of the Heart of New York Award for Achievement in Cardiovascular Science and Medicine and several distinguished teaching awards. He serves on panels issuing clinical practice guidelines for management of patients with cardiovascular disorders, including atrial fibrillation, peripheral arterial disease, cerebrovascular disease and stroke. He chairs the ACC/AHA/ACP Task Force on Clinical Competence and Training, served on the FDA Cardiovascular and Renal Drugs Advisory Committee and is Chair-Elect of the ACC/AHA Task Force on Practice Guidelines. He has authored books and journal articles and maintained a stream of clinical investigations involving an array of cardiovascular disorders. He has been a member of the ATLAS group since its inception.

Cardiovascular Medicine Associates
Guggenheim Pavilion
1190 Fifth Avenue – 1 West
New York, NY 10029
Phone: 212-241-7243
Fax: 212-831-2195
Email: jonathan.halperin@mountsinai.org


Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.

Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, Kessler CM, Turpie AG, Cutler NR, Hiatt WR; Antithrombotic Trials Leadership and Steering (ATLAS) Group.

Updated Clinical Practice Guidelines on Heart Failure: an International Alignment.

Antman EM, Bax J, Chazal RA, Creager MA, Filippatos G, Halperin JL, Houser S, Lindenfeld J, Pinto FJ, Vardas P, Walsh MN, Williams KA, Zamorano JL.

Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.

Pokorney SD, Piccini JP, Stevens SR, Patel MR, Pieper KS, Halperin JL, Breithardt G, Singer DE, Hankey GJ, Hacke W, Becker RC, Berkowitz SD, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee & Investigators; ROCKET AF Steering Committee Investigators.

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.

Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Lokhnygina Y, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Califf RM, Fox KA, Patel MR; ROCKET AF Steering Committee & Investigators.

For additional research publications please visit: https://www.researchgate.net/researcher/38562887_Jonathan_L_Halperin